The TSPYL2 antibody is designed to detect the TSPYL2 (testis-specific Y-encoded-like protein 2), a member of the TSPY-like gene family located on the X chromosome. TSPYL2. also known as CXYorf2 or DENTT, is a nucleoprotein implicated in cell cycle regulation, chromatin remodeling, and transcriptional control. It interacts with cell cycle regulators like CDK2 and p53. suggesting roles in tumor suppression and apoptosis. While its homolog TSPY is testis-specific and linked to male fertility, TSPYL2 exhibits broader tissue expression, including the brain, liver, and reproductive organs, though its precise biological functions remain under investigation.
Antibodies targeting TSPYL2 are primarily used in research to explore its involvement in cancer, neurodevelopmental disorders, and reproductive biology. Studies highlight its dual role as both a tumor suppressor and oncogene, depending on cellular context. For example, TSPYL2 downregulation is associated with hepatocellular carcinoma and glioblastoma progression, while overexpression correlates with poor prognosis in ovarian cancer. These antibodies enable detection via techniques like Western blotting, immunohistochemistry, and immunofluorescence, aiding in mapping TSPYL2's subcellular localization (primarily nuclear) and expression patterns in normal vs. diseased tissues. Commercial TSPYL2 antibodies are typically monoclonal or polyclonal, validated for specificity against epitopes in conserved N-terminal or C-terminal regions. Recent interest focuses on its potential as a biomarker or therapeutic target, particularly in cancers with dysregulated cell cycle pathways.